AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
MINNEAPOLIS, April 06, 2018 -- Inspire Medical Systems, Inc. ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint lead book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from any of the following sources:
- BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
